Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial ...

The US Food and Drug Administration (FDA) has approved Edwards Lifesciences' SAPIEN 3 transcatheter aortic valve replacement (TAVR) platform for the treatment of patients with asymptomatic severe ...

SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...

Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences' Sapien 3 Ultra system. The artificial heart valve is pushed through the blood vessels via a catheter and ...

Edwards Lifesciences Corp.’s posted fourth quarter results slightly ahead of expectations, but indicated that the first quarter of 2025 might not be as bright. The company expects growth for both its ...

Edwards Lifesciences has persuaded CMS to publish an updated tracking sheet for TAVR national coverage analysis. The move is causing CMS to reconsider its previous stance on covering transcatheter ...

SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...